Goldman Sachs downgrades Bath & Body Works to Sell, cuts target to $19
Goldman Sachs analyst Kate McShane downgraded Bath & Body Works from Neutral to Sell, reducing the price target to $19 from $23. This contrasts with Morgan Stanley's Equal-Weight rating and $22 target.
*this image is generated using AI for illustrative purposes only.
Goldman Sachs analyst Kate McShane has downgraded Bath & Body Works from Neutral to Sell and lowered the price target to $19 from $23. The revised rating reflects a more cautious outlook on the stock's performance relative to the broader market.
Rating and Valuation
The downgrade significantly alters the market sentiment for the company. The table below summarizes the key details of the analyst's update:
| Metric | Details |
|---|---|
| Rating | Sell |
| Previous Rating | Neutral |
| Price Target | $19 |
| Previous Price Target | $23 |
| Coverage Analyst | Kate McShane |
The shift to a Sell rating suggests that the stock is now expected to underperform the analyst's coverage universe. This move follows a previous reinstatement of coverage by Morgan Stanley analyst Alex Straton, who had assigned an Equal-Weight rating with a price target of $22.
What specific factors led Goldman Sachs to adopt a more cautious outlook on Bath & Body Works?
How might this downgrade influence other analysts' ratings and price targets for the company?
What potential market or economic conditions could exacerbate the stock's underperformance?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
